全文获取类型
收费全文 | 3146篇 |
免费 | 221篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 19篇 |
儿科学 | 126篇 |
妇产科学 | 35篇 |
基础医学 | 446篇 |
口腔科学 | 67篇 |
临床医学 | 280篇 |
内科学 | 645篇 |
皮肤病学 | 113篇 |
神经病学 | 107篇 |
特种医学 | 82篇 |
外科学 | 496篇 |
综合类 | 148篇 |
一般理论 | 2篇 |
预防医学 | 261篇 |
眼科学 | 84篇 |
药学 | 296篇 |
中国医学 | 37篇 |
肿瘤学 | 136篇 |
出版年
2023年 | 28篇 |
2022年 | 111篇 |
2021年 | 114篇 |
2020年 | 73篇 |
2019年 | 94篇 |
2018年 | 123篇 |
2017年 | 68篇 |
2016年 | 79篇 |
2015年 | 80篇 |
2014年 | 122篇 |
2013年 | 153篇 |
2012年 | 231篇 |
2011年 | 201篇 |
2010年 | 121篇 |
2009年 | 108篇 |
2008年 | 172篇 |
2007年 | 174篇 |
2006年 | 175篇 |
2005年 | 136篇 |
2004年 | 112篇 |
2003年 | 127篇 |
2002年 | 95篇 |
2001年 | 67篇 |
2000年 | 75篇 |
1999年 | 52篇 |
1998年 | 25篇 |
1997年 | 30篇 |
1996年 | 17篇 |
1995年 | 21篇 |
1994年 | 13篇 |
1993年 | 20篇 |
1992年 | 50篇 |
1991年 | 37篇 |
1990年 | 26篇 |
1989年 | 52篇 |
1988年 | 21篇 |
1987年 | 17篇 |
1986年 | 26篇 |
1985年 | 12篇 |
1984年 | 12篇 |
1983年 | 16篇 |
1981年 | 9篇 |
1980年 | 6篇 |
1979年 | 7篇 |
1978年 | 6篇 |
1976年 | 5篇 |
1975年 | 8篇 |
1973年 | 7篇 |
1966年 | 4篇 |
1943年 | 4篇 |
排序方式: 共有3380条查询结果,搜索用时 15 毫秒
51.
The effect of a six-month exercise program on very low-density lipoprotein apolipoprotein B secretion in type 2 diabetes 总被引:3,自引:0,他引:3
Alam S Stolinski M Pentecost C Boroujerdi MA Jones RH Sonksen PH Umpleby AM 《The Journal of clinical endocrinology and metabolism》2004,89(2):688-694
The dyslipidemia and insulin resistance of type 2 diabetes can be improved by aerobic exercise. The effect of 6 months supervised exercise on very low-density lipoprotein (VLDL) apolipoprotein B metabolism was investigated in patients with type 2 diabetes. Moderately obese patients (n = 18) were randomized into supervised (n = 9) and unsupervised (n = 9) exercise groups. All patients were given a training session and a personal exercise program and asked to exercise four times per week at 70% maximal oxygen uptake for 6 months. Patients in the supervised group had a weekly session with an exercise trainer. VLDL apolipoprotein (apo)B metabolism was measured with an infusion of 1-(13)C leucine before and after 6 months of the exercise program. Supervised exercise for 6 months resulted in a significant within-group decrease in percent hemoglobin A1c (P < 0.001), body fat (P < 0.004), nonesterified fatty acid (P < 0.04), and triglycerides (P < 0.05) and an increase in insulin sensitivity (P < 0.01). There was a decrease in VLDL apoB pool size (160.8 +/- 42.6 to 84.9 +/- 23.2 mg, P < 0.01) and VLDL apoB secretion rate (11.3 +/- 2.6 to 5.5 +/- 2.0 mg/kg.d, P < 0.05) with no change in fractional catabolic rate. In a between-group comparison, the decrease in VLDL apoB secretion rate in the supervised group did not achieve significance. This study demonstrates that in type 2 diabetes, a supervised exercise program reduces VLDL apoB pool size, which may be due to a decrease in VLDL apoB secretion rate. 相似文献
52.
Giovanna Leoni Philipp-Alexander Neumann Nazila Kamaly Miguel Quiros Hikaru Nishio Hefin R. Jones Ronen Sumagin Roland S. Hilgarth Ashfaqul Alam Gabrielle Fredman Ioannis Argyris Emile Rijcken Dennis Kusters Chris Reutelingsperger Mauro Perretti Charles A. Parkos Omid C. Farokhzad Andrew S. Neish Asma Nusrat 《The Journal of clinical investigation》2015,125(3):1215-1227
Epithelial restitution is an essential process that is required to repair barrier function at mucosal surfaces following injury. Prolonged breaches in epithelial barrier function result in inflammation and further damage; therefore, a better understanding of the epithelial restitution process has potential for improving the development of therapeutics. In this work, we demonstrate that endogenous annexin A1 (ANXA1) is released as a component of extracellular vesicles (EVs) derived from intestinal epithelial cells, and these ANXA1-containing EVs activate wound repair circuits. Compared with healthy controls, patients with active inflammatory bowel disease had elevated levels of secreted ANXA1-containing EVs in sera, indicating that ANXA1-containing EVs are systemically distributed in response to the inflammatory process and could potentially serve as a biomarker of intestinal mucosal inflammation. Local intestinal delivery of an exogenous ANXA1 mimetic peptide (Ac2-26) encapsulated within targeted polymeric nanoparticles (Ac2-26 Col IV NPs) accelerated healing of murine colonic wounds after biopsy-induced injury. Moreover, one-time systemic administration of Ac2-26 Col IV NPs accelerated recovery following experimentally induced colitis. Together, our results suggest that local delivery of proresolving peptides encapsulated within nanoparticles may represent a potential therapeutic strategy for clinical situations characterized by chronic mucosal injury, such as is seen in patients with IBD. 相似文献
53.
Shazli Azmi Maryam Ferdousi Ioannis N. Petropoulos Georgios Ponirakis Uazman Alam Hassan Fadavi Omar Asghar Andrew Marshall Andrew J. Atkinson Wendy Jones Andrew J.M. Boulton Mitra Tavakoli Maria Jeziorska Rayaz A. Malik 《Diabetes care》2015,38(8):1502-1508
OBJECTIVEImpaired glucose tolerance (IGT) through to type 2 diabetes is thought to confer a continuum of risk for neuropathy. Identification of subjects at high risk of developing type 2 diabetes and, hence, worsening neuropathy would allow identification and risk stratification for more aggressive management.RESULTSTen subjects who developed type 2 diabetes had a significantly lower CNFD (P = 0.003), CNBD (P = 0.04), and CNFL (P = 0.04) compared with control subjects at baseline and a further reduction in CNFL (P = 0.006), intraepidermal nerve fiber density (IENFD) (P = 0.02), and mean dendritic length (MDL) (P = 0.02) over 3 years. Fifteen subjects who remained IGT and 5 subjects who returned to normal glucose tolerance had no significant baseline abnormality on CCM or IENFD but had a lower MDL (P < 0.0001) compared with control subjects. The IGT subjects showed a significant decrease in IENFD (P = 0.02) but no change in MDL or CCM over 3 years. Those who returned to NGT showed an increase in CNFD (P = 0.05), CNBD (P = 0.04), and CNFL (P = 0.05), but a decrease in IENFD (P = 0.02), over 3 years.CONCLUSIONSCCM and skin biopsy detect a small-fiber neuropathy in subjects with IGT who develop type 2 diabetes and also show a dynamic worsening or improvement in corneal and intraepidermal nerve morphology in relation to change in glucose tolerance status. 相似文献
54.
Xin Chen Jim Graham Mohammad A. Dabbah Ioannis N. Petropoulos Georgios Ponirakis Omar Asghar Uazman Alam Andrew Marshall Hassan Fadavi Maryam Ferdousi Shazli Azmi Mitra Tavakoli Nathan Efron Maria Jeziorska Rayaz A. Malik 《Diabetes care》2015,38(6):1138-1144
OBJECTIVE
Quantitative assessment of small fiber damage is key to the early diagnosis and assessment of progression or regression of diabetic sensorimotor polyneuropathy (DSPN). Intraepidermal nerve fiber density (IENFD) is the current gold standard, but corneal confocal microscopy (CCM), an in vivo ophthalmic imaging modality, has the potential to be a noninvasive and objective image biomarker for identifying small fiber damage. The purpose of this study was to determine the diagnostic performance of CCM and IENFD by using the current guidelines as the reference standard.RESEARCH DESIGN AND METHODS
Eighty-nine subjects (26 control subjects and 63 patients with type 1 diabetes), with and without DSPN, underwent a detailed assessment of neuropathy, including CCM and skin biopsy.RESULTS
Manual and automated corneal nerve fiber density (CNFD) (P < 0.0001), branch density (CNBD) (P < 0.0001) and length (CNFL) (P < 0.0001), and IENFD (P < 0.001) were significantly reduced in patients with diabetes with DSPN compared with control subjects. The area under the receiver operating characteristic curve for identifying DSPN was 0.82 for manual CNFD, 0.80 for automated CNFD, and 0.66 for IENFD, which did not differ significantly (P = 0.14).CONCLUSIONS
This study shows comparable diagnostic efficiency between CCM and IENFD, providing further support for the clinical utility of CCM as a surrogate end point for DSPN. 相似文献55.
56.
Md. Sazzadul Islam Bhuyian Ronald Saxton Khaled Hasan Jahed Masud Fatema Zohura Shirajum Monira Shwapon Kumar Biswas M. Tasdik Hasan Tahmina Parvin Ismat Minhaj Kazi Md. Zillur Rahman Nowshin Papri Mahamud‐ur Rashid Lubaba Sharin Alana Teman Elizabeth D. Thomas Kelsey Alland Alain Labrique David A. Sack Jamie Perin Munirul Alam Christine Marie George 《Tropical medicine & international health : TM & IH》2020,25(8):985-995
57.
Steven J. McElroy Shannon L. Castle Jessica K. Bernard Dana Almohazey Catherine J. Hunter Brandon A. Bell Denise Al Alam Larry Wang Henri R. Ford Mark R. Frey 《The American journal of pathology》2014,184(10):2768-2778
Necrotizing enterocolitis (NEC) affects up to 10% of premature infants, has a mortality of 30%, and can leave surviving patients with significant morbidity. Neuregulin-4 (NRG4) is an ErbB4-specific ligand that promotes epithelial cell survival. Thus, this pathway could be protective in diseases such as NEC, in which epithelial cell death is a major pathologic feature. We sought to determine whether NRG4-ErbB4 signaling is protective in experimental NEC. NRG4 was used i) in the newborn rat formula feeding/hypoxia model; ii) in a recently developed model in which 14- to 16-day-old mice are injected with dithizone to induce Paneth cell loss, followed by Klebsiella pneumoniae infection to induce intestinal injury; and iii) in bacterially infected IEC-6 cells in vitro. NRG4 reduced NEC incidence and severity in the formula feed/hypoxia rat model. It also reduced Paneth cell ablation–induced NEC and prevented dithizone-induced Paneth cell loss in mice. In vitro, cultured ErbB4−/− ileal epithelial enteroids had reduced Paneth cell markers and were highly sensitive to inflammatory cytokines. Furthermore, NRG4 blocked, through a Src-dependent pathway, Cronobacter muytjensii–induced IEC-6 cell apoptosis. The potential clinical relevance of these findings was demonstrated by the observation that NRG4 and its receptor ErbB4 are present in human breast milk and developing human intestine, respectively. Thus, NRG4-ErbB4 signaling may be a novel pathway for therapeutic intervention or prevention in NEC.Necrotizing enterocolitis (NEC) is a devastating intestinal disease primarily affecting premature infants. In the United States, NEC afflicts 7% of infants weighing <1500 g.1 In addition to prematurity, risk factors include hypoxia, bacterial colonization of the intestine, and formula feeding.2 The development of NEC seems to be multifactorial, and patients may have any combination of risk factors at the time of presentation. The current disease model is that the immature gut barrier, along with defects in endogenous antimicrobial activity,3 allows bacterial translocation across the epithelium, triggering an inflammatory response that further worsens gut barrier function. Pathogenic bacteria,4, 5 inflammatory cytokines such as tumor necrosis factor (TNF),6, 7, 8 and Paneth cell dropout3 have all been associated with human NEC and contribute to NEC-like injury in animal models.Available therapy for either prevention or treatment of NEC is limited, and patients currently face a mortality rate of approximately 30%.9, 10, 11 Breast-fed infants have a lower risk of NEC than their formula-fed peers,12, 13 and a variety of studies have attempted to identify and characterize factors in human milk that confer this protection. Candidate protective molecules to date include immunoglobulins, oligosaccharides, lactoferrin, and soluble growth factors, such as epidermal growth factor (EGF)14 and heparin-binding EGF-like growth factor (HB-EGF).15 In rat and mouse models, enteral administration of either EGF16, 17 or HB-EGF18 decreases the incidence and severity of NEC. The primary receptor for both EGF and HB-EGF is EGF receptor (EGFR), the prototypic member of the ErbB receptor tyrosine kinase family. However, HB-EGF also activates ErbB4, a member of the ErbB family whose potential role in the developing gut and NEC is not known.ErbB4 has unique biochemical properties distinguishing it from other ErbB family members. Compared with EGFR, ErbB2, or ErbB3, it recognizes a broader collection of ligands, including the EGF-like growth factors HB-EGF and betacellulin as well as the heregulin/neuregulin molecules.19 At the same time, the ErbB4 c-terminus contains a distinct and somewhat restricted set of functional docking sites for downstream effectors20 and is thus predicted to elicit divergent cellular effects on activation versus other family members. In fact, we recently demonstrated that neuregulin-4 (NRG4), an ErbB4-specific ligand that does not bind or activate other family members, including EGFR,21 specifically promotes survival but not migration or proliferation of mouse colon epithelial cells.22 Thus, ErbB4 is a potentially unique and selective target for therapeutic protection in diseases in which intestinal epithelial cell death is a major pathologic feature.We previously reported that ErbB4 is up-regulated in adult human and murine colon inflammation in vivo23 and that ErbB4 overexpression protects cultured colonocytes from cytokine-induced apoptosis in a ligand-dependent manner.24 Furthermore, i.p. NRG4 administration reduces the severity of acute murine dextran sulfate sodium colitis.22 Thus, it seems that ErbB4 induction is a natural compensatory response meant to preserve the epithelium rather than part of disease pathology and that ErbB4 activation with exogenous ligand is protective against induced inflammation. However, the role of this signaling pathway in the small intestine, or during development, has not been described. We hypothesized that ErbB4 and its ligands have a protective role in the small bowel during postnatal development, particularly in the setting of NEC-associated acute injury and inflammation. To advance our understanding of ErbB4 biology in intestinal homeostasis and disease, we tested the hypothesis that NRG4-ErbB4 signaling is protective in experimental NEC. 相似文献
58.
Akash Bhattacharya Steven L. Alam Thomas Fricke Kaneil Zadrozny Jaroslaw Sedzicki Alexander B. Taylor Borries Demeler Owen Pornillos Barbie K. Ganser-Pornillos Felipe Diaz-Griffero Dmitri N. Ivanov Mark Yeager 《Proceedings of the National Academy of Sciences of the United States of America》2014,111(52):18625-18630
59.
60.
ObjectiveSeveral studies have assessed the effect of angiotensin converting enzyme inhibitors (ACEIs) on arterial stiffness and wave reflections as measured by pulse wave velocity (PWV) and augmentation index (AIx), respectively. We conducted a meta-analysis to investigate this effect in comparison to placebo and to other antihypertensive agents. Additionally, we investigated this effect when ACEIs are combined with other antihypertensive agents and in comparison to a combination of antihypertensive agents.MethodsMEDLINE, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from inception to May 2011 on randomised controlled trials (RCTs) which assessed the effect of ACEIs on arterial stiffness vs. placebo or no treatment and ACEIs vs. angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), β-blockers and diuretics. RCTs which assessed the effect of ACEIs combined with other antihypertensives or compared ACEIs with a combination of antihypertensives were also sought. Data from included RCTs were pooled with use of fixed and random effects meta-analysis of the weighted mean change differences between the comparator groups. Heterogeneity across studies was assessed with the I2 statistic.ResultsIn 5 trials including 469 patients, treatment with ACEIs (n = 227) vs. placebo (n = 216) significantly reduced PWV (pooled mean change difference ?1.69, 95% C.I. ?2.05, ?1.33, p < 0.00001 with insignificant heterogeneity). In 9 trials which included 378 patients, treatment with ACEIs (n = 178) insignificantly reduced PWV when compared with other antihypertensives (ARBs, CCBs, β-blockers, diuretics and a combination of ACEI and ARB) (n = 220) (pooled mean change difference ?0.19, 95% C.I. ?0.59, 0.21, p = 0.36, I2 = 0%). ACEI effect on AIx in comparison to placebo was assessed in 7 trials. Treatment with ACEIs significantly reduced AIx (pooled mean change difference ?3.79, 95% C.I. ?5.96, ?1.63, p = 0.0006) with significant heterogeneity. In 7 trials, treatment with ACEIs significantly reduced AIx when compared with other antihypertensives (pooled mean change difference ?1.84, 95% C.I. ?3, ?0.68, p = 0.002, I2 = 32%, p for heterogeneity = 0.11). However, this effect was only significant when compared with β-blockers (pooled mean change difference ?1.6, 95% C.I. ?2.84, ?0.36, p = 0.01). Mean BP differences between baseline and end of treatment did not predict the treatment (ACEI) induced changes in PWV.ConclusionsACEIs reduce PWV and AIx which are markers of arterial stiffness and wave reflections in patients with different pathological conditions. However, due to the lack of high quality and properly powered RCTs, it is not clear whether ACEIs are superior to other antihypertensive agents in their effect on arterial stiffness. The ability of ACEIs to reduce arterial stiffness (PWV) seems to be independent of its ability to reduce BP. 相似文献